Conditions: Growth Disorder Idiopathic Short Stature
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 54
Healthy volunteers: no

Brief summary:
This trial is conducted in Asia. The aim of this trial is to evaluate the efficacy and safety of recombinant human growth hormone (hGH) in subjects with idiopathic short stature in Korea.

Detailed description:

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: somatropin
Intervention descriptions: intervention 1: A weekly dosage of 0.469 mg of somatropin per kg of body weight per week will be injected subcutaneously (under the skin) in the evening in 7 days per week.

Protocol document: